Bayuh Cherinet Adera

@dndi.org

Senior Market Access Manager, Access program
Drugs for Neglected Diseases initiative

Bayuh Cherinet Adera


                  Download Compact PDF  
https://researchid.co/cherinet

RESEARCH, TEACHING, or OTHER INTERESTS

Public Health, Environmental and Occupational Health, Infectious Diseases, General Medicine
10

Scopus Publications

275

Scholar Citations

10

Scholar h-index

10

Scholar i10-index

Scopus Publications

  • The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study
    Shewaye Belay Tessema, Tadyos Hagos, Genet Kehasy, Lucy Paintain, Cherinet Adera, Merce Herrero, Margriet den Boer, Haftom Temesgen, Helen Price, Afework Mulugeta
    Plos Neglected Tropical Diseases, 2024
    Background Visceral leishmaniasis (VL) is an important public health problem, which mainly affects the poor rural dwelling communities in Low- and Middle-Income Countries. However, little is known about the health and economic burdens of this disease in East Africa, including Ethiopia. The aim of this study was to assess the household level economic burden of VL among affected communities in Tigray, Northern Ethiopia. Methods Between April and August 2020, a cross-sectional household survey was conducted on 96 patients who had been treated for VL within 12 months prior to the survey, in six districts of Tigray. Data on households’ health seeking behavior, direct and indirect costs and coping strategies were collected using a structured questionnaire and the responses were analyzed using SPSS software. Results Most (82%) of the patients surveyed were males and the majority (74%) of them were between 16 and 30 years of age. The education level of participants was very low: over 33% had not received any form of education; 48% of patients were farmers dependent on subsistence agriculture and about 32% were daily laborers. Just under half of household families (46%) resided in “poor houses” with structures made from entirely local materials. Forty-one percent of patients from the surveyed households had traveled 48 to 72 kilometers to reach VL treatment hospitals. The median total household cost for one VL episode was estimated to be US$ 214. This is equated to 18% of the mean total annual household income or 72.5% of annual per capita income of the study population. More than 80% of the households surveyed incurred catastrophic costs of VL, where this is defined as exceeding 10% of annual household income. The median delay between the onset of symptoms and arrival at a care provider hospital was 37 days; once the patient arrived at hospital, the median delay during diagnosis was 3 days. Direct and indirect costs represented 44% and 56% of the total costs incurred, respectively. To cope with VL treatment costs, 43% of the households used more than one coping strategy: 48% took out loans, 43% sold livestock and 31% of households mobilized cash savings. Conclusions VL in Tigray is concentrated among young males with low educational background and mostly engaged in subsistence economic activities. Despite the free diagnostic and treatment provisions that were available at public hospitals at the time of the study, our work shows that the household economic burden of the disease had significant impact among VL-affected communities in Tigray. Initiating community awareness towards prevention, early treatment seeking and decentralization of VL treatment centers are strongly recommended. In addition, we recommend efforts to reduce household treatment costs through transport and food provisions for patients (and their accompanying carers where possible) or through cash reimbursement for patients who complete treatment at public hospitals, in order to reduce the barriers to seeking treatment for this life-threatening disease.
  • Understanding the risk perception of visceral leishmaniasis exposure and the acceptability of sandfly protection measures among migrant workers in the lowlands of Northwest Ethiopia: a health belief model perspective
    Resom Berhe, Mark Spigt, Francine Schneider, Lucy Paintain, Cherinet Adera, Adane Nigusie, Zemichael Gizaw, Yihenew Alemu Tesfaye, Dia-Eldin A. Elnaiem, Mekuriaw Alemayehu
    BMC Public Health, 2022
    Background Visceral leishmaniasis (VL) is the leading cause of health concerns among Ethiopian migrant workers. Understanding risk perception and health-protective behavior are significant challenges in the prevention and eradication of the disease. As a result, studies are required to assess these important epidemiological factors, which will provide guidance on how to assist migrant workers in taking preventive measures against VL. Method We conducted qualitative research among migrant workers on seasonal agricultural farms in Northwest Ethiopia between June and November 2019 to assess their perception of the risk of contracting VL and their willingness to use protective measures against the disease. Seventeen focus group discussions and 16 key informant interviews were conducted to study migrant workers’ risk perception in relation to sandfly bite exposure and use of sandfly control measures. For analysis, all interviews were recorded, transcribed, and translated. ATLASti was used to perform qualitative content analysis on the data. Result Migrant workers are fearful of VL because of previous exposure and the disease’s prevalence in the area. They believe, however, that VL is a minor illness that is easily treated. While Insecticide Treated Nets (ITNs) are widely accepted as a protective measure, there are still reservations about using them due to the seasonality of the transmission, difficulties in hanging them on farm areas, and a preference for alternative traditional practices. Regardless of perceived self-efficacy, the central cues were the message delivered by the health workers and an increase in sandfly bite irritation. Based on the findings, three levels of intervention modalities are suggested: 1) increasing pre-arrival awareness through outdoor media (posters, stickers, billboards), 2) encouraging proper use of protective measures upon arrival at farm camps, and 3) informing departing workers on disease recognition and best practices for health-seeking continuous use of protective measures at home. Conclusion This finding suggests that VL prevention interventions should focus on individuals’ perceptions in order to promote consistent use of protective measures. The findings are highly useful in planning effective interventions against VL.
  • Moving from control to elimination of Visceral Leishmaniasis in East Africa
    Louise Kathini Makau-Barasa, Duncan Ochol, Kelly A. Yotebieng, Cherinet B. Adera, Dziedzom K. de Souza
    Frontiers in Tropical Diseases, 2022
    Visceral leishmaniasis (VL) is arguably one of the deadliest neglected tropical diseases. People in poverty bear the largest burden of the disease. Today, the largest proportion of persons living with VL reside in the Eastern African countries of Ethiopia, Kenya, Somalia, South Sudan, and Sudan. These East African countries are among the top 10 countries reporting the highest number of cases and deaths. If left undiagnosed and untreated, VL almost always results in death. Subsequently, there is a need for integrated efforts across human, animal, and vector-control programs to address the scourge of VL in East Africa. In the East African region, the challenges including socio-cultural beliefs, poor health system, political instability, and limited epidemiological understanding impede the implementation of effective VL control strategies. The availability of funding, as well as diagnostics and treatment options, are also devastatingly limited. Furthermore, given the realities of climate change and population movement in the region, to effectively address the scourge of visceral leishmaniasis in East Africa, a regional approach is imperative. In this paper, we highlight some of the key challenges and opportunities to effectively move towards an effective control, and eventually elimination, of VL in East Africa. To do this, we underline the need for a fully integrated program in East Africa, inclusive of effective diagnostics and treatment, to effectively reduce and eliminate the burden of VL in the region, subsequently paving the way to achieve global elimination goals.
  • Control of visceral leishmaniasis in East Africa: Fragile progress, new threats
    Elin Hoffmann Dahl, Hamdan Mustafa Hamdan, Lexson Mabrouk, Sultani Hadley Matendechero, Tesfahun Bishaw Mengistie, Mousab Siddig Elhag, Mounir Lado, Cherinet Adera, Atia Abdalla Atia, Julien Potet, Margriet den Boer, Koert Ritmeijer, Jorge Alvar, Fabiana Alves, Gabriel Alcoba
    BMJ Global Health, 2021
    ### Summary box Significant progress has been made in reducing the global burden of visceral leishmaniasis (also known as ‘kala azar’), a vectorborne disease that is 100% fatal if left untreated, but new threats are on the horizon. So far, the success has been particularly striking in India, Bangladesh and Nepal, where reported cases have declined from more than 77 000 in 1992 to under 3200 in 2019.1 2 In contrast, in East Africa, existing diagnostics and treatments are not as effective and progress has been more fragile. Around 11 000 cases were reported …
  • Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
    Samson Tekalign, Cherinet Adera, Margriet Den Boer, Hirpha Miecha, Ashenafi Zewde, Dagnachew Mulugeta, Tesfahun Bishawu, Weyuma Birru, Awoke Lema, Tilahun Sahlu, Fabiana Alves, Marcel Manzi, Kudakwashe Takarinda, Johan Van Griensven
    Journal of Infection in Developing Countries, 2020
    Introduction: In three health care facilities in the Oromia region, the aim of this study is to report on 1) the number of VL cases registered over time (2013-2018) and 2) the clinical profile, type of treatment used and response to treatment.
 Methodology: A retrospective cohort study was conducted among all VL cases admitted with a diagnosis of VL.
 Results: A total of 434 VL cases were registered at the three health facilities, but patient files were available for only 188. Most (51.6%) were children and only three presented with VL relapse. 78 (41.5%) of the 188 patients presented within one month of symptom onset. Concurrent severe acute malnutrition (27.1%), tuberculosis (6.4%) and malaria (6.4%) were common. There were only two cases with HIV coinfection. Fourty-three percent were treated with antimonials, 34% with antimonials combined with paromomycin and 23% with AmBisome. Amongst the 188 patients with patient files there were no deaths and one treatment failure. Six months outcome data were however missing for all. Aggregated data from the 434 VL cases reported three deaths, two treatment failures and one relapse.
 Conclusions: Children were most commonly affected, suggesting long-term endemicity. While short-term outcomes are encouraging, long-term follow-up data are required.
  • Impact of education on knowledge and practice of kala azar preventive measures among seasonal and migrant agricultural workers in northwest Ethiopia
    Mekuriaw Alemayehu, Lucy Paintain, Cherinet Adera, Resome Berhe, Abebaw Gebeyehu, Zemichael Gizaw, Merce Herrero, Abate Mulugeta Beshah, Margriet Den Boer, Adane Nigusie, Meseret Alem, Enyew Yechale, Dia-Eldin A. Elnaiem
    American Journal of Tropical Medicine and Hygiene, 2020
    Kala azar occurs among seasonal and migrant agricultural workers in northwest Ethiopia and accounts for almost 60% of the disease burden in the country. We conducted a quantitative study on the level of knowledge and practice of this vulnerable group in relation to kala azar transmission and acceptability of its vector control tools. A total of 403 workers were randomly selected from eight farms using a purposive sampling technique. Knowledge and practice scores were calculated based on 12 and 9 core questions, respectively. Binary logistic regression was used to identify factors associated with knowledge and practice. A large gap in knowledge of the disease and the vector was evident with 61.8%, 24.6%, and 13.6% of the workers having poor, moderate, and good levels of knowledge scores, respectively. Similarly, 95% of the seasonal workers reported poor level of use of protective measures against the bite of the sand fly vector. Good level of knowledge about kala azar and its sand fly vector was statistically associated with formal education (adjusted odds ratio [AOR] = 2.11; 95% CI = 1.17, 3.80; P < 0.05) and previous exposure to health education (AOR = 4.72; 95% CI = 1.99, 11.16; P < 0.001). Despite poor current knowledge and practice, a large proportion of the study participants showed interest in using vector control tools if made available, with 78% of the seasonal and migrant workers expressing some willingness to pay for different measures that can protect against sand fly bites. Therefore, we strongly recommend that comprehensive health education and vector control programs should be provided to these workers.
  • Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient
    Charles Abongomera, Tullia Battaglioli, Cherinet Adera, Koert Ritmeijer
    International Journal of Infectious Diseases, 2019
    Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of visceral leishmaniasis caused by Leishmania donovani. PKDL treatment options are few and have severe limitations. In East-Africa, the standard treatment of PKDL is with daily painful potentially toxic sodium stibogluconate injections, administered for a prolonged duration of 30-60 days. In the Indian subcontinent, PKDL is mainly treated with miltefosine, a safer orally administered drug. However, in East-Africa, there is very limited experience in the use of miltefosine for treatment of severe PKDL, with only one published case report. Here we report a severe PKDL case in an Ethiopian HIV patient successfully treated with oral miltefosine (100mg/day for 28 days). Miltefosine was efficacious, safe and well tolerated, suggesting that it can play an important role in the treatment of severe PKDL also in East-African patients. Further research is warranted.
  • Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study
    Rebecca Marie Coulborn, Tesfay Gebregzabher Gebrehiwot, Martin Schneider, Sibylle Gerstl, Cherinet Adera, Mercè Herrero, Klaudia Porten, Margriet den Boer, Koert Ritmeijer, Jorge Alvar, Abrahim Hassen, Afework Mulugeta
    Plos Neglected Tropical Diseases, 2018
    BACKGROUND: Ethiopia bears a high burden of visceral leishmaniasis (VL). Early access to VL diagnosis and care improves clinical prognosis and reduces transmission from infected humans; however, significant obstacles exist. The approximate 250,000 seasonal mobile workers (MW) employed annually in northwestern Ethiopia may be particularly disadvantaged and at risk of VL acquisition and death. Our study aimed to assess barriers, and recommend interventions to increase access, to VL diagnosis and care among MWs. METHODOLOGY/PRINCIPAL FINDINGS: In 2017, 50 interviews and 11 focus group discussions were conducted with MWs, mobile residents, VL patients and caretakers, community leaders and healthcare workers in Kafta Humera District, Tigray. Participants reported high vulnerability to VL among MWs and residents engaged in transitory work. Multiple visits to health facilities were consistently needed to access VL diagnosis. Inadequate healthcare worker training, diagnostic test kit unavailability at the primary healthcare level, lack of VL awareness, insufficient finances for care-seeking and prioritization of income-generating activities were significant barriers to diagnosis and care. Social (decision-making and financial) support strongly and positively influenced care-seeking; workers unable to receive salary advances, compensation for partial work, or peer assistance for contract completion were particularly disadvantaged. Participants recommended the government/stakeholders intervene to ensure: MWs access to bed-nets, food, shelter, water, and healthcare at farms or sick leave; decentralization of diagnostic tests to primary healthcare facilities; surplus medications/staff during the peak season; improved referral/feedback/reporting/training within the health system; free comprehensive healthcare for all VL-related services; and community health education. CONCLUSIONS/SIGNIFICANCE: Contrary to what health policy for VL dictates in this endemic setting, study participants reported very poor access to diagnosis and, consequently, significantly delayed access to treatment. Interventions tailored to the socio-economic and health needs of MWs (and other persons suffering from VL) are urgently needed to reduce health disparities and the VL burden.
  • Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients during and after Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial
    Ermias Diro, Koert Ritmeijer, Marleen Boelaert, Fabiana Alves, Rezika Mohammed, Charles Abongomera, Raffaella Ravinetto, Maaike De Crop, Helina Fikre, Cherinet Adera, Harry van Loen, Achilleas Tsoumanis, Wim Adriaensen, Asrat Hailu, Johan van Griensven
    Clinical Infectious Diseases, 2018
    Background: We have conducted a single-arm trial evaluating monthly pentamidine secondary prophylaxis (PSP) to prevent visceral leishmaniasis (VL) relapse in Ethiopian human immunodeficiency virus-infected patients. Outcomes at 12 months of PSP have been previously reported, supporting PSP effectiveness and safety. However, remaining relapse-free after PSP discontinuation is vital. We now report outcomes and associated factors for a period of up to 2.5 years after initiating PSP, including 1-year follow-up after PSP discontinuation. Methods: The trial had 3 phases: (1) 12 months of PSP; (2) a 6-month PSP extension period if CD4 count was ≤200 cells/μL at month 12; and (3) 12-month follow-up after stopping PSP. The probability of relapse and risk factors were calculated using Kaplan-Meier methods and Cox regression analysis. Results: For the 74 patients included, final study outcomes were as follows: 39 (53%) relapse-free, 20 (27%) relapsed, 5 (7%) deaths, 10 (14%) lost to follow-up. The 2-year risk of relapse was 36.9% (95% confidence interval, 23.4%-55.0%) and was highest for those with a history of VL relapse and low baseline CD4 count. Forty-five patients were relapse-free and in follow-up at month 12 of PSP. This included 28 patients with month 12 CD4 counts >200 cells/µL, remaining relapse-free after PSP discontinuation. Among the 17 with month 12 CD4 count <200 cells/µL, 1 relapsed and 3 were lost during the PSP extension period. During 1-year post-PSP follow-up, 2 patients relapsed and 1 was lost to follow-up. No PSP-related serious adverse events were reported during the PSP-extension/post-PSP follow-up period. Conclusions: It seems safe to discontinue PSP at month 12 CD4 counts of >200 cells/µL. The management of those failing to reach this level remains to be defined. Clinical Trials Registration: NCT01360762.
  • Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study
    Ermias Diro, Koert Ritmeijer, Marleen Boelaert, Fabiana Alves, Rezika Mohammed, Charles Abongomera, Raffaella Ravinetto, Maaike De Crop, Helina Fikre, Cherinet Adera, Robert Colebunders, Harry van Loen, Joris Menten, Lutgarde Lynen, Asrat Hailu, Johan van Griensven
    Plos Neglected Tropical Diseases, 2015
    Visceral leishmaniasis (VL) has become an important opportunistic infection in persons with HIV-infection in VL-endemic areas. The co-infection leads to profound immunosuppression and high rate of annual VL recurrence. This study assessed the effectiveness, safety and feasibility of monthly pentamidine infusions to prevent recurrence of VL in HIV co-infected patients.

RECENT SCHOLAR PUBLICATIONS

  • The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study
    SB Tessema, T Hagos, G Kehasy, L Paintain, C Adera, M Herrero, ...
    PLoS neglected tropical diseases 18 (10), e0012423 , 2024
    2024
    Citations: 10
  • Moving from control to elimination of Visceral Leishmaniasis in East Africa
    LK Makau-Barasa, D Ochol, KA Yotebieng, CB Adera, DK de Souza
    Frontiers in Tropical Diseases 3, 965609 , 2022
    2022
    Citations: 29
  • Understanding the risk perception of visceral leishmaniasis exposure and the acceptability of sandfly protection measures among migrant workers in the lowlands of Northwest …
    R Berhe, M Spigt, F Schneider, L Paintain, C Adera, A Nigusie, Z Gizaw, ...
    BMC Public Health 22 (1), 989 , 2022
    2022
    Citations: 21
  • A Qualitative Study to Understand the Risk Perception About Exposure to the Bites of Sandflies Among Migrant Workers in the Lowlands of Northwest Ethiopia. A Health Belief …
    R Berhe, M Spigt, F Schneider, L Paintain, C Adera, A Nigusie, Z Gizaw, ...
    2021
  • Control of visceral leishmaniasis in East Africa: fragile progress, new threats
    EH Dahl, HM Hamdan, L Mabrouk, SH Matendechero, TB Mengistie, ...
    BMJ Global Health 6 (8) , 2021
    2021
    Citations: 23
  • Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
    S Tekalign, C Adera, M Den Boer, H Miecha, A Zewde, D Mulugeta, ...
    The Journal of Infection in Developing Countries 14 (06.1), 42S-47S , 2020
    2020
    Citations: 10
  • Impact of education on knowledge and practice of kala azar preventive measures among seasonal and migrant agricultural workers in northwest Ethiopia
    M Alemayehu, L Paintain, C Adera, R Berhe, A Gebeyehu, Z Gizaw, ...
    The American Journal of Tropical Medicine and Hygiene 102 (4), 758 , 2020
    2020
    Citations: 14
  • The catastrophic economic burden of visceral leishmaniasis in Bangladesh, India, Ethiopia and Sudan: financial risk protection is not enough
    L Paintain, L Boudarene, M Pearson, M Herrero, V Aggarwal, T Edwards, ...
    2019 World Congress on Health Economics , 2019
    2019
    Citations: 2
  • Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
    CA Charles Abongomera, TB Tullia Battaglioli, CA Cherinet Adera, ...
    2019
  • Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient
    C Abongomera, T Battaglioli, C Adera, K Ritmeijer
    International Journal of Infectious Diseases 81, 221-224 , 2019
    2019
    Citations: 14
  • Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study
    RM Coulborn, TG Gebrehiwot, M Schneider, S Gerstl, C Adera, M Herrero, ...
    PLoS neglected tropical diseases 12 (11), e0006778 , 2018
    2018
    Citations: 35
  • Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single …
    ED Ermias Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, ...
    2018
  • Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus–coinfected patients during and after pentamidine secondary prophylaxis in ethiopia: a single …
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical Infectious Diseases 66 (3), 444-451 , 2018
    2018
    Citations: 29
  • Clinical mentoring via mobile teams-a new approach to visceral Leishmaniasis care in resource-constrained settings in Africa
    M den Boer, M Herrero, M Lado, A Atiaby, D Ochol, C Adera, J Alvar, ...
    TROPICAL MEDICINE & INTERNATIONAL HEALTH 22, 176-177 , 2017
    2017
  • Long-term clinical outcomes in visceral leishmaniasis-HIV co-infected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical Infectious Diseases: an official publication of the Infectious … , 2017
    2017
    Citations: 8
  • Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study.
    ED Ermias Diro, K Ritmeijer, M Boelaert, F Alves, RM Rezika Mohammed, ...
    2015
  • Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    PLoS neglected tropical diseases 9 (10), e0004087 , 2015
    2015
    Citations: 80
  • Use of Pentamidine as Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical management of Visceral Leishmaniasis in HIV Patients in Ethiopia, 127 , 2015
    2015

MOST CITED SCHOLAR PUBLICATIONS

  • Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    PLoS neglected tropical diseases 9 (10), e0004087 , 2015
    2015
    Citations: 80
  • Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: A qualitative study
    RM Coulborn, TG Gebrehiwot, M Schneider, S Gerstl, C Adera, M Herrero, ...
    PLoS neglected tropical diseases 12 (11), e0006778 , 2018
    2018
    Citations: 35
  • Moving from control to elimination of Visceral Leishmaniasis in East Africa
    LK Makau-Barasa, D Ochol, KA Yotebieng, CB Adera, DK de Souza
    Frontiers in Tropical Diseases 3, 965609 , 2022
    2022
    Citations: 29
  • Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus–coinfected patients during and after pentamidine secondary prophylaxis in ethiopia: a single …
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical Infectious Diseases 66 (3), 444-451 , 2018
    2018
    Citations: 29
  • Control of visceral leishmaniasis in East Africa: fragile progress, new threats
    EH Dahl, HM Hamdan, L Mabrouk, SH Matendechero, TB Mengistie, ...
    BMJ Global Health 6 (8) , 2021
    2021
    Citations: 23
  • Understanding the risk perception of visceral leishmaniasis exposure and the acceptability of sandfly protection measures among migrant workers in the lowlands of Northwest …
    R Berhe, M Spigt, F Schneider, L Paintain, C Adera, A Nigusie, Z Gizaw, ...
    BMC Public Health 22 (1), 989 , 2022
    2022
    Citations: 21
  • Impact of education on knowledge and practice of kala azar preventive measures among seasonal and migrant agricultural workers in northwest Ethiopia
    M Alemayehu, L Paintain, C Adera, R Berhe, A Gebeyehu, Z Gizaw, ...
    The American Journal of Tropical Medicine and Hygiene 102 (4), 758 , 2020
    2020
    Citations: 14
  • Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient
    C Abongomera, T Battaglioli, C Adera, K Ritmeijer
    International Journal of Infectious Diseases 81, 221-224 , 2019
    2019
    Citations: 14
  • The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study
    SB Tessema, T Hagos, G Kehasy, L Paintain, C Adera, M Herrero, ...
    PLoS neglected tropical diseases 18 (10), e0012423 , 2024
    2024
    Citations: 10
  • Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
    S Tekalign, C Adera, M Den Boer, H Miecha, A Zewde, D Mulugeta, ...
    The Journal of Infection in Developing Countries 14 (06.1), 42S-47S , 2020
    2020
    Citations: 10
  • Long-term clinical outcomes in visceral leishmaniasis-HIV co-infected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single-arm clinical trial
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical Infectious Diseases: an official publication of the Infectious … , 2017
    2017
    Citations: 8
  • The catastrophic economic burden of visceral leishmaniasis in Bangladesh, India, Ethiopia and Sudan: financial risk protection is not enough
    L Paintain, L Boudarene, M Pearson, M Herrero, V Aggarwal, T Edwards, ...
    2019 World Congress on Health Economics , 2019
    2019
    Citations: 2
  • A Qualitative Study to Understand the Risk Perception About Exposure to the Bites of Sandflies Among Migrant Workers in the Lowlands of Northwest Ethiopia. A Health Belief …
    R Berhe, M Spigt, F Schneider, L Paintain, C Adera, A Nigusie, Z Gizaw, ...
    2021
  • Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
    CA Charles Abongomera, TB Tullia Battaglioli, CA Cherinet Adera, ...
    2019
  • Long-term clinical outcomes in visceral leishmaniasis/human immunodeficiency virus-coinfected patients during and after pentamidine secondary prophylaxis in Ethiopia: a single …
    ED Ermias Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, ...
    2018
  • Clinical mentoring via mobile teams-a new approach to visceral Leishmaniasis care in resource-constrained settings in Africa
    M den Boer, M Herrero, M Lado, A Atiaby, D Ochol, C Adera, J Alvar, ...
    TROPICAL MEDICINE & INTERNATIONAL HEALTH 22, 176-177 , 2017
    2017
  • Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study.
    ED Ermias Diro, K Ritmeijer, M Boelaert, F Alves, RM Rezika Mohammed, ...
    2015
  • Use of Pentamidine as Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients
    E Diro, K Ritmeijer, M Boelaert, F Alves, R Mohammed, C Abongomera, ...
    Clinical management of Visceral Leishmaniasis in HIV Patients in Ethiopia, 127 , 2015
    2015